Efficacy of transcranial alternating current stimulation in treating chronic insomnia and the impact of age on its effectiveness: A multisite randomized, double-blind, parallel-group, placebo-controlled study

被引:5
|
作者
Zhu, Xiaolin [1 ]
Ren, Yanping [2 ]
Tan, Shuping [1 ]
Ma, Xin [2 ]
机构
[1] Peking Univ, Beijing HuiLongGuan Hosp, HuiLongGuan Clin Med Sch, Beijing 100096, Peoples R China
[2] Capital Med Univ, Being Anding Hosp, 5 Ankang Lane,Deshengmenwai Ave, Beijing 100088, Peoples R China
关键词
Transcranial alternating current stimulation; Insomnia; Randomized controlled trial; Pittsburgh sleep quality index; SLEEP QUALITY; ELECTRIC-STIMULATION; DISORDER; ELECTROSTIMULATION; MANAGEMENT; GUIDELINE; THERAPY;
D O I
10.1016/j.jpsychires.2023.12.037
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Insomnia is a significant health issue associated with various systemic diseases. Transcranial alternating current stimulation (tACS) has been proposed as a potential intervention for insomnia. However, the efficacy and mechanisms of tACS in chronic insomnia remain unclear. Accordingly, this study aimed to investigate the efficacy of tACS in treating chronic insomnia in adults and assess the impact of age on its effectiveness using a large sample from two centers. Methods: A total of 120 participants with chronic insomnia underwent 20 daily sessions of tACS (duration: 40 min, frequency: 77.5 Hz, and intensity: 15 mA) or sham tACS targeting the forehead and both mastoid areas over 4 weeks. Assessments were conducted at baseline, post-treatment, and 4-week follow-up. Primary outcomes included sleep quality and efficiency, onset latency, total sleep time, and daily disturbances. Secondary outcomes included depression, anxiety, and clinical impression. Results: Compared with the control group, the tACS group demonstrated improved sleep quality and efficiency, increased total sleep time, and reduced daily disturbance (allps < 0.01). Moreover, tACS had a significant effect on clinical impression (p < 0.001), but not depression and anxiety scores. Subgroup analyses revealed that older participants experienced significant benefits from tACS in sleep quality, efficiency, and overall insomnia reduction at post-treatment and follow-up (p < 0.001). Notably, improved insomnia correlated with attenuated depressive and anxiety symptoms. Conclusions: These findings suggest that tACS may be an effective intervention for chronic insomnia within an eight-week timeframe, and age affects the response to tACS in terms of insomnia improvement.
引用
收藏
页码:253 / 261
页数:9
相关论文
共 50 条
  • [41] Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
    Burge, James
    Sansone, Valeria
    McDermott, Michael
    Smith, Patty
    Herr, Barbara
    Tawil, Alrabi
    Pandya, Shree
    Kissel, John
    Ciafaloni, Emma
    Shieh, Perry
    Ralph, Jeffrey
    Amato, Anthony
    Cannon, Stephen
    Trivedi, Jaya
    Barohn, Richard
    Crum, Brian
    Mitsumoto, Hiroshi
    Pestronk, Alan
    Meola, Giovanni
    Conwit, Robin
    Jasek, Mark
    Hanna, Michael
    Griggs, Robert
    NEUROLOGY, 2016, 86
  • [42] Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial
    Ciampi, Ethel
    Uribe-San-Martin, Reinaldo
    Carcamo, Claudia
    Cruz, Juan Pablo
    Reyes, Ana
    Reyes, Diego
    Pinto, Carmen
    Vasquez, Macarena
    Burgos, Rafael A.
    Hancke, Juan
    BMC NEUROLOGY, 2020, 20 (01)
  • [43] Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis
    Yoshifuji, Hajime
    Ishii, Tomonori
    Ohashi, Hiroki
    Yoshizawa, Katsunori
    Mihoya, Maki
    Nishikawa, Kazuko
    Nakaoka, Yoshikazu
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2025, 9 (02)
  • [44] A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
    Collin, C.
    Ehler, E.
    Waberzinek, G.
    Alsindi, Z.
    Davies, P.
    Powell, K.
    Notcutt, W.
    O'Leary, C.
    Ratcliffe, S.
    Novakova, I.
    Zapletalova, O.
    Pikova, J.
    Ambler, Z.
    NEUROLOGICAL RESEARCH, 2010, 32 (05) : 451 - 459
  • [45] Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta®) and its effect on total sleep time, headache frequency, and daytime functioning: A randomized, double-blind, placebo-controlled, parallel-group, pilot study
    Spierings, Egilius L. H.
    McAllister, Peter J.
    Bilchik, Tanya R.
    CRANIO-THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE, 2015, 33 (02): : 115 - 121
  • [46] The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study
    Ghali, Jalal K.
    Orlandi, Cesare
    Abraham, William T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (06) : 642 - 651
  • [47] Repetitive transcranial magnetic stimulation (rTMS) in the prophylactic treatment of chronic migraine: a double-blind, randomized, placebo-controlled study
    Libera, D. Dalla
    Colombo, B.
    Nuara, A.
    Straffi, L.
    Spagnolo, F.
    Fichera, M.
    Coppi, E.
    Ferrari, L.
    Di Maggio, G.
    Houdayer, E.
    Chieffo, R.
    Zangen, A.
    Comi, G.
    Leocani, L.
    JOURNAL OF NEUROLOGY, 2013, 260 : S199 - S200
  • [48] Efficacy and safety of GQ-lab daily in patients with irritable bowel syndrome: A randomized, double-blind, placebo-controlled, parallel-group study
    Shin, C. M.
    Choi, Y. J.
    Yoon, H.
    Park, Y. S.
    Kim, N.
    Lee, D. H.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [49] Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine
    Spierings, Egilius L. H.
    Brandes, Jan Lewis
    Kudrow, David B.
    Weintraub, James
    Schmidt, Peter C.
    Kellerman, Donald J.
    Tepper, Stewart J.
    CEPHALALGIA, 2018, 38 (02) : 215 - 224
  • [50] Efficacy of Violet oil, a traditional Iranian formula, in patients with chronic insomnia: A randomized, double-blind, placebo-controlled study
    Feyzabadi, Zohre
    Rezaeitalab, Fariborz
    Badiee, Shapour
    Taghipour, Ali
    Moharari, Fatemeh
    Soltanifar, Atefeh
    Ahmadpour, Mohammad Reza
    JOURNAL OF ETHNOPHARMACOLOGY, 2018, 214 : 22 - 28